Teva launches first U.S. generic Cialis as Eli Lilly braces for loss of its ED blockbuster

Look out, Eli Lilly: Teva is launching its generic version of the erectile dysfunction drug Cialis in the U.S. Sales of the heavily advertised branded version, which brought in $2.3 billion last year, are expected to fall to $55 million by 2022, putting pressure on Lilly to forge into new and lucrative markets.